News >

Selective Inhibitors of Rare Mutations Show Encouraging Activity in NSCLC

Caroline Seymour
Published: Tuesday, Jul 16, 2019

Jessica J Lin, MD

Jessica J Lin, MD

Selective inhibitors for patients with non–small cell lung cancer (NSCLC) with rare oncogenic drivers, such as RET fusions, KRASG12C mutations, and MET exon 14 alterations, are showing high response rates in clinical trials, explained Jessica Jiyeong Lin, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x